title: Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
abstract: Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
authors.affiliation: Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Janie
authors.initials: J
authors.lastname: Parrino
authors.forename: Lewis H
authors.initials: LH
authors.lastname: McCurdy
authors.forename: Brenda D
authors.initials: BD
authors.lastname: Larkin
authors.forename: Ingelise J
authors.initials: IJ
authors.lastname: Gordon
authors.forename: Steven E
authors.initials: SE
authors.lastname: Rucker
authors.forename: Mary E
authors.initials: ME
authors.lastname: Enama
authors.forename: Richard A
authors.initials: RA
authors.lastname: Koup
authors.forename: Mario
authors.initials: M
authors.lastname: Roederer
authors.forename: Robert T
authors.initials: RT
authors.lastname: Bailer
authors.forename: Zoe
authors.initials: Z
authors.lastname: Moodie
authors.forename: Lin
authors.initials: L
authors.lastname: Gu
authors.forename: Lihan
authors.initials: L
authors.lastname: Yan
authors.forename: Barney S
authors.initials: BS
authors.lastname: Graham
mesh_terms: D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D012899:Smallpox / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*
chemical_list: C078786:DryVax vaccine; D012900:Smallpox Vaccine